
Celcuity (CELC) Stock Forecast & Price Target
Celcuity (CELC) Analyst Ratings
Bulls say
Celcuity Inc. has experienced a substantial stock price appreciation of approximately 608% year-to-date, significantly outperforming industry benchmarks. The company’s positive outlook is further supported by the recent increase in gedatolisib sales estimates to $70 million, $462 million, and $827 million for the years 2025, 2026, and 2027 respectively, indicating a stronger market position due to expedited regulatory reviews and anticipated early share gains. Additionally, the successful results from the VIKTORIA-1 trial, demonstrating improved safety in HR+/HER2- breast cancer patients, have led to a raised probability of product launch from 80% to 90%, underscoring the promising prospects for Celcuity's pipeline.
Bears say
The excerpts indicate that Celcuity is experiencing a cautious outlook due to several financial and operational factors. The company's estimated R&D spending shows a slight decline, while total GAAP operating expenses have not significantly decreased, raising concerns about the efficiency of capital allocation. Additionally, the potential for delays in FDA decisions regarding gedatolisib and competition from larger pharmaceutical companies could result in adverse pricing impacts and lower-than-expected revenues, leading to a reassessment of the current stock valuation.
This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.
Celcuity (CELC) Analyst Forecast & Price Prediction
Start investing in Celcuity (CELC)
Order type
Buy in
Order amount
Est. shares
0 shares